Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC

By afschroeder • October 21, 2026

Brown T, Lara MS, Jiang F, Garon EB, Goldman JW, Riess JW, Blakely CM. Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC. JTO Clin Res Rep. 2026 Aug 31;7(11):101072. doi: 10.1016/j.jtocrr.2026.101072. PMID: 42898856; PMCID: PMC13679293.

Tags: acquired resistance, Capmatinib, Hematology/Oncology, MET, metastatic NSCLC, Publications, Trametinib

Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, Chan SL, Edeline J, Klümpen HJ, Yau T, Verslype C, Ozaka M, Bouattour M, Park[...]

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]

B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman

Cai J, Sin D, Varda M, Lewis L, Yeh J. B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman. Clin Case Rep. 2026[...]